Healthcare Cost and Impact of Persistent Orofacial Pain by Durham, Justin et al.
Citation:  Durham,  Justin,  Shen,  Jing,  Breckons,  Matthew,  Steele,  Jimmy,  Araujo-Soares, 
Vera,  Exley,  Catherine and Vale,  Luke (2016)  Healthcare Cost  and Impact  of  Persistent 
Orofacial Pain. Journal of Dental Research, 95 (10). pp. 1147-1154. ISSN 0022-0345 
Published by: SAGE
URL:  http://dx.doi.org/10.1177/0022034516648088 
<http://dx.doi.org/10.1177/0022034516648088>
This  version  was  downloaded  from  Northumbria  Research  Link: 
http://nrl.northumbria.ac.uk/29828/
Northumbria University has developed Northumbria Research Link (NRL) to enable users to 
access the University’s research output. Copyright © and moral rights for items on NRL are 
retained by the individual author(s) and/or other copyright owners.  Single copies of full items 
can be reproduced,  displayed or  performed,  and given to  third parties in  any format  or 
medium for personal research or study, educational, or not-for-profit purposes without prior 
permission or charge, provided the authors, title and full bibliographic details are given, as 
well  as a hyperlink and/or URL to the original metadata page. The content must  not  be 
changed in any way. Full items must not be sold commercially in any format or medium 
without  formal  permission  of  the  copyright  holder.   The  full  policy  is  available  online: 
http://nrl.northumbria.ac.uk/policies.html
This document may differ from the final, published version of the research and has been 
made available online in accordance with publisher policies. To read and/or cite from the 
published version of the research, please visit the publisher’s website (a subscription may be 
required.)
  
1 
Healthcare cost & impact of persistent orofacial pain: DEEP 
Study’s cohort 
J.Durham
1,2
, NIHR Clinician Scientist & Senior Lecturer in Oral Surgery and Orofacial Pain 
J. Shen
2
, Senior Research Associate in Health Economics 
M. Breckons
2
, Research Associate 
JG Steele
1,3
, Professor of Oral Health Services Research 
V Araujo-Soares
3
, Senior Lecturer in Health Psychology 
C Exley
3
, Professor of Qualitative Health Research 
L Vale
2
, Health Foundation Chair in Health Economics 
 
1
Centre for Oral Health Research & Institute of Health & Society 
School of Dental Sciences 
Framlington Place 
Newcastle University  
NE2 4BW 
UK 
Justin.Durham@ncl.ac.uk 
Tel: +44  (0)191 208 6000 
Fax: +44  (0)191 208 6137 
 
2
Health Economics Group 
Institute of Health & Society 
The Baddiley-Clark Building 
Richardson Road  
Newcastle upon Tyne  
NE2 4AX   
 
3
Institute of Health & Society 
The Baddiley-Clark Building 
Richardson Road  
Newcastle upon Tyne  
NE2 4AX 
 
Keywords: Chronic pain, Facial pain, Orofacial pain, Healthcare utilization, Cost analysis, 
Graded Chronic Pain Scale 
 
Word count: 3338 
References: 40 
Figures: 1 
Tables: 4 
E-appendix with supplemental data and tables. 
 
Funding: This study and JD are funded by a NIHR Clinician Scientist award (NIHR-CS-011-
003). The views expressed in this publication are those of the author (s) and not necessarily 
those of the NHS, the National Institute for Health Research, or the Department of Health in 
the United Kingdom. The authors have no conflicts of interest to declare. 
Conflicts of interest 
All authors have completed the Unified Competing Interest form at 
www.icmje.org/coi_disclosure.pdf  (available on request from the corresponding author) and 
declare that  (1) All authors have support from no commercial companies for the submitted 
work;  (2) No authors have relationships with companies that might have an interest in the 
submitted work in the previous 3 years;  (3) their spouses, partners, or children have no 
financial relationships that may be relevant to the submitted work; and  (4) All authors have 
no non-financial interests that may be relevant to the submitted work 
  
2 
  
3 
Abstract 
Few data are available on the healthcare costs of those suffering from 
persistent orofacial pain (POFP). This cohort and cost analysis study 
examined the direct costs of POFP from the perspective of the health care 
provider (specifically, the UK NHS) in 2012 pounds sterling and sought to 
identify if dichotomised (high [IV-IIb]; low [IIa-0]) graded chronic pain scale 
(GCPS) status is predictive of the total cost of healthcare over the last six 
months. The healthcare utilisation of 198 patients with POFP were collected 
using a structured interview and validated “use of services and productivity” 
questionnaire. Unit costs were used with these utilisation data to calculate 
direct healthcare costs in three categories: consultation; medication; 
appliances and interventions. Consultation costs were a significant proportion 
of cumulative healthcare cost (p<0.001). Dichotomised GCPS status was 
predictive of increased healthcare cost over the last six months accounting for 
an average increase of £366 (95%CI: 135 - 598. p<0.01) when moving from a 
low GCPS status to a high GCPS status. Given dichotomised GCPS status’ 
predictive capability and the success of stratified models of care for other 
persistent pain conditions dichotomised GCPS status may offer an opportunity 
to help determine stratification of care for patients with POFP.  
Perspective: 
This study identifies the high demand on healthcare services from POFP 
patients mediated by the large number of consultations undergone and that 
dichotomised GCPS might help screen patients in a stratified care model and 
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thereby focus care and allocate healthcare resources more efficiently, 
irrespective of who pays the healthcare provider’s costs.   
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Introduction 
 
Persistent orofacial pain  (POFP) is used to describe a group of 
heterogeneous illnesses including: Temporomandibular disorders, Burning 
Mouth Syndrome, Persistent Dentoalveolar Pain, Trigeminal Neuralgia, 
Atypical Facial pain (Persistent idiopathic facial pain) (Macfarlane et al. 2001; 
De Leeuw and Klasser 2013). Given POFP’s nature and range of symptoms it 
can present to either medicine or dentistry and may need management from 
both (Madland and Feinmann 2001). POFP frequently becomes a chronic 
illness and can be difficult to manage exerting major impacts on health and 
quality of life (Shueb et al. 2015). 
 
Management of chronic illnesses is subject to long-term use of healthcare 
services, but there are always only finite amounts of resources available to 
provide these services.  The use of resources in one particular manner 
precludes their use in other desirable ways.  The benefits forgone represent 
the opportunity cost, or economic cost, of using resources (Drummond et al. 
2005).  Opportunity costs can be estimated by valuing the use of services in 
monetary terms.  Costs themselves can be directly (e.g. medication costs) or 
indirectly incurred (e.g. travel costs) related to healthcare.  Knowledge of the 
costs incurred provides a baseline to consider whether changing the manner 
in which resources are used will be worth the benefits that might be provided; 
for example, changing the way POFP patients access or receive healthcare to 
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improve the effectiveness and efficiency of the services used and perhaps 
even recommend different levels of use of services (and hence cost) on the 
basis of predicted need. A good example of how predicted need might be 
established is through the use of the graded chronic pain scale (GCPS).  The 
GCPS status and its dichotomisation has been shown to help inform the type, 
and extent, of therapeutic intervention required for persistent pain (Von Korff 
et al. 1992; Dworkin et al. 2002; Von Korff and Dunn 2008; Manfredini et al. 
2013; Kotiranta et al. 2015). The dichotomisation of the GCPS may offer a 
screening instrument to help determine care pathways, or resource allocation, 
for patients. 
 
Currently, few and limited data are available on POFP patients’ healthcare 
costs (Glaros et al. 1995; Shimshak et al. 1997; White et al. 2001) and/or 
GCPS status, making it hard to predict whether potential changes in the 
provision of care (and hence costs) are worthwhile. As part of a larger 
programme of research addressing this need (DEEP study 
http://research.ncl.ac.uk/deepstudy (Durham et al. 2014)), this paper 
examines the direct costs of POFP using UK healthcare utilisation data. The 
study aims to identify the major components of healthcare cost and if 
dichotomised GCPS status (Von Korff et al. 1992; Dworkin et al. 2002) is 
predictive of total cost of healthcare in the last six months.  
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Methods 
The DEEP study received ethical approval (NRES Reference: 12/YH/0338) 
and its methods are summarised below. An online open access protocol is 
also available (Durham et al. 2014).  
Sample 
An a priori sample size of 200 was determined (α=0.05) in order to detect, 
with 80% power, a moderate effect size of 0.4 (Cohen 1988) between groups 
using two-tailed inferential statistics. This sample size allows the use of 
regression analyses in order to examine up to thirty predictors of costs of 
managing POFP at a moderate effect size (α=0.05; β=0.8) (Green 1991). The 
a priori predictor of interest derived from the literature was dichotomised 
graded chronic pain status, given its prognostic validity and role in helping 
determine appropriate treatment regimens (Von Korff et al. 1992; Von Korff 
and Dunn 2008; Manfredini et al. 2013; Kotiranta et al. 2015). 
To allow for a 20% attrition rate through loss to follow-up and non-response, 
the target was to recruit 240 individuals from primary (community) and 
secondary (hospital/specialist) based settings across the North-East of 
England (Durham et al. 2014).  
To be eligible for the study individuals must: 
• Have orofacial pain for three months or more  
• Screen positive as having a musculoskeletal, and or 
neuropathic/vascular origin to their pain (Hapak et al. 1994; Gonzalez 
et al. 2011) 
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• Be over 18 years of age 
• Be able to give informed consent in English.  
Exclusion criteria were that an individual: 
• Screened as only suffering from Dentoalveolar pain  
• Had insufficient knowledge of English to be able to complete reliable 
consent or data collection. 
Measures and instruments 
Six instruments completed by participants are reported here: EQ-5D-5L for 
generic quality of life (Herdman et al. 2011); Graded Chronic Pain Scale 
(GCPS (Von Korff et al. 1992)); Multidimensional Pain inventory (MPI Version 
3 (Kerns et al. 1985)); Patient Health Questionnaire 4 (PHQ-4 (Kroenke et al. 
2009)); Use of services and productivity questionnaire (USPQ (Wordsworth 
and Thompson 2001)); Illness Perceptions Questionnaire  (IPQ-R (Moss-
Morris et al. 2002)). Full descriptions, scoring instructions, and interpretation 
guides for each instrument are provided in the e-appendix.  
Dichotomised GCPS status was generated by calculating the standard five 
point ordinal GCPS rating (0 to IV in order of ascending disability) and 
applying the algorithm provided by Dworkin et al (Dworkin et al. 2002) to 
subdivide Grade II into II “high disability” (IIb) or II “low disability” (IIa). This 
algorithm converts the five point standard GCPS rating into six points and 
allows dichotomisation into low GCPS (grades 0-IIa) and high GCPS (grades 
IIb-IV) states. 
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Procedures and data collection 
Primary care recruitment occurred from 10 dental practices and 25 medical 
practices, representative of all deciles of the index of multiple deprivation 
index (UK multifactorial deprivation measure). Secondary care recruitment 
occurred at specialist clinics in neurology, oral and maxillofacial surgery, 
dental emergency clinics, oral medicine and restorative dentistry. All recruiting 
centres used a standardised proforma to refer individuals to the study whom 
they felt would fit the appropriate inclusion criteria. Upon receipt of the 
proforma the research team undertook a standardised approach to screening 
and then recruitment (Durham et al. 2014).  
Eligibility screening used validated self-complete screening questionnaires 
(Hapak et al. 1994; Gonzalez et al. 2011) to identify the origin of the 
participants’ pain complaint as either musculoskeletal (sensitivity 63.1%; 
specificity 85.9%), neuropathic/vascular (sensitivity 66.3%; specificity 96.8%), 
or a combined origin if the instruments used could not definitively distinguish 
between origins. Individuals screening positive were invited to participate in 
the study, informed written consent taken, and their screening group was then 
used as their pain origin for the analyses. Those screening negative were 
thanked for their interest and took no further part in the study unless a clinical 
diagnosis was available from a specialist clinician that suggested this was a 
false negative in which case they were included and assigned a grouping in 
accordance with their specialist’s clinical diagnosis. 
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Initial data collection was by trained interviewers who conducted baseline, 
structured interviews with questions relating to the individual’s: employment; 
education level; duration of pain; gross monthly income; numbers and details 
of healthcare contacts and treatments received. The reference period for 
these questions was the duration of the pain complaint up to the interview. 
Interviewers systematically examined the individual’s account of events over 
the duration of their complaint and recorded the data on a standardised 
proforma. These interview data allowed the estimation of healthcare utilisation 
and, in combination with healthcare unit costs, the per annum cost of the 
POFP condition over the duration of the complaint.  
In contrast, the healthcare utilisation of the patient over the last six months 
were specifically examined using the USPQ and these data in combination 
with the healthcare unit costs allowed the calculation of the healthcare costs 
over the last six months. The USPQ was issued along with all other study 
instruments following the interview.  
Data analyses 
Estimation of costs 
Costs of POFP to healthcare providers were grouped into three broad 
categories: consultation costs (visits to healthcare professional for 
discussion); medication costs; appliance (dental/surgical) and intervention 
(dental/medical/surgical) costs. All costs are at 2012 prices in pounds Sterling; 
the year the DEEP study started. Unit costs and sources used are detailed in 
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the supplemental e-appendix (Table S1, supplemental appendix), briefly 
described below.  
All unit costs were multiplied against appropriate healthcare utilisation data 
either from the USPQ, to calculate the last six months costs, or data gathered 
in the structured interview, to calculate the total cost up to entry into the study.  
Per annum costs were then calculated by dividing the total cost up to entry 
into the study by the participant’s duration of pain. 
 
Dental primary care consultation unit costs were based on the average 
consultation time in primary care, the British Dental Association’s standard 
contract for primary care and the 2012/13 dental earnings national report 
(HSCIC 2014). Other medical and allied health professionals’ consultation unit 
costs in primary care were calculated using the Personal Social Services 
Research Unit’s (PSSRU) unit costs for healthcare (2012).  Secondary care 
consultation unit costs were identified from the NHS reference costs for the 
financial year 2011-2012 (DoH 2012). 
 
Non-proprietary medication dosing regimens were multiplied against price 
data from the British National Formulary (Joint Formulary Committee 2012) 
and do not include pharmacy charges to the patient.  
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Primary dental care appliance and intervention unit costs were calculated 
using the number of units of dental activity (UDA) specified in the dental 
contract (NHS 2005) for the item of treatment reported multiplied by the 
average UDA cost (£25.61) for England and Wales in 2012 (personal 
communication from the British Dental Association via freedom of information 
request from the U.K. Department of Health in 2012).  All participants paid a 
proportion of the burden of the total cost of the dental care with the state.  
Other medical and allied health professionals’ appliance and intervention unit 
costs were calculated using the PSSRU unit costs for healthcare (2012). 
Secondary care treatment unit costs were taken as the mean unit value from 
the appropriate NHS reference cost for the financial year 2011-2012 (DoH 
2012). Secondary care dental costs for hard stabilisation and soft splints were 
not available in the reference costs and were obtained from a local hospital.  
Statistical procedures 
STATA version 13 was used for all analyses (Stata Statistical Software. 
StataCorp LP, College Station, TX, USA). Standard descriptive statistics were 
calculated. Parametric inferential statistical tests were used to examine 
differences in impact of pain between the dichotomised high and low GCPS 
groups and also in the analysis of drop-out from the study. Bootstrapping 
using the bias corrected accelerated method with 1000 repetitions was 
conducted to produce confidence intervals around the point estimate of the 
mean total cost and three cumulative cost categories: consultations, 
medication, and appliance and intervention costs. A bootstrapped one-way 
ANOVA was then used to examine differences between costs in the three 
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cumulative cost categories in line with recommended practice for cost data 
(Barber and Thompson 2004). 
Scatter plots were used to examine outliers and crosscheck validity of data 
entry. Different functional forms of regression were tested (linear and log-
linear), but the best performing model, as would be expected and 
recommended as best practice by the literature (Mihaylova et al. 2011), was a 
generalised gamma linear model (GLM) using an identify link function. This 
GLM model was used to examine the relationship between total cost over the 
last six months and the dichotomised GCPS status, controlling for 
demographic and socioeconomic factors. A modified park test was used to 
confirm the family for the generalised linear model.  
Deterministic sensitivity analyses (DSA) were conducted on variables where 
there could be uncertainty over the unit costs: primary dental care 
consultation costs, and secondary care consultation and treatment costs. DSA 
used alternate higher and lower values for the unit costs in order to 
recalculate the total cost at its highest and lowest plausible values. In the case 
of those variables calculated from healthcare reference costs, the upper and 
lower quartile values were used as the basis for the DSA (DoH 2012). For all 
other variables one standard deviation, as given by the source used (e-
appendix – table S1), was used to explore the range of cost for the DSA.  
In the instruments used in the study there were no missing data in the GCPS 
or the MPI. EQ-5D-5L had five singular missing data points (0.5%) and these 
were imputed. PHQ-4 had missing data in 10 individuals and therefore the 
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summary score was incalculable. IPQ-R had 3% of data missing across all 
domains after imputation per domain there were five to seven participants per 
domain where domain scores could not be calculated (>1 missing item). 
Imputation procedures are explained in the e-appendix. 
 
The present report follows the STROBE statement regarding cohort studies 
(von Elm et al. 2007).  
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Results 
From a total of 387 individuals referred for eligibility screening by the 
participating centres (Durham et al. 2014), 279 (72%) agreed to be screened. 
There was no significant difference in age (t(366)=1.24; p=0.215; 95%CI 
difference -1.52, 6.73years) or gender (X2(1, n=386)=0.66; p=0.261) between 
those declining the invitation to be screened and those who accepted the 
invitation.   
Figure 1 demonstrates the flow of participants and dropout rates through the 
study following screening. The final 198 participants used for this study did not 
differ significantly in gender (X2(1, n=239)=0.20; p=0.658), ethnicity 
(F(6,232)=0.16; p=0.988), duration (t(237)=1.43; p=0.154; 95%CI difference -
12.12,76.65months) or origin of pain (F(2,236)=2.13; p=0.122) from those 
who dropped out. Those participating were, however, older than those who 
dropped out (t(237)=3.78; p<0.01; 95%CI difference 5.28,16.87years).  
 
Females made up the majority of those recruited (81%) and the most frequent 
screening result for the pain’s origin was musculoskeletal (43%, Table 1). The 
majority of the sample were in employment (59%, Table 1) with the mean 
monthly gross salary being £940 (±1018 s.d.). Table S2 details the pain’s 
history and impact demonstrating that the participants had a variable duration 
of pain with a mean duration of 108.4 (±130.3 s.d.) months and over this 
period they had consulted on average 4 healthcare professionals (±2 s.d.) in 
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relation to their complaint with most (93%) having experienced at least one 
treatment for their pain. 
 
Table 2 demonstrates healthcare costs since the complaint began with a 
significant difference evident between consultation, medication, and appliance 
and intervention costs. Consultation costs were significantly higher than both 
of the other two cost categories in both the per annum (F(2,591)=71.08 
P<0.001) and last six month’s (F(2,591)=70.30; P<0.001) costs and therefore 
accounted for the largest proportion of the cumulative healthcare cost.  
 
The deterministic sensitivity analyses, which varied the unit costs to account 
for uncertainties over the costs of some variables, suggests that the lowest 
plausible total mean cost per annum is £292 (95%CI: 239 - 345) and the 
highest is £473 (95%CI: 383 - 563). Similarly the lowest plausible total mean 
cost over the last six months is £544 (95%CI: 455 - 634) and the highest is 
£766 (95%CI: 607 - 925).  
 
Due to missing data in some of the sociodemographic variables, the sample 
size used in the GLM regression model was 175. The model’s results, (Table 
3), demonstrate that dichotomised GCPS is a statistically significant predictor 
of the total pain management costs over the last 6 months, controlling for age, 
gender, origin of pain, duration of pain, employment status, level of education, 
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and index of multiple deprivation. Moving from a low to a high GCPS status 
increased cost by £366 (95%CI: 135 - 598. p<0.01). Costs in each cost 
category along with sociodemographic and economic status are also broken 
down by dichotomised GCPS status in the e-appendix (Tables S3 & S4). 
 
The high GCPS state (IIb-IV) produces significantly more biopsychosocial 
impact than the low state as measured by the MPI, PHQ-4 and EQ-5D-5L 
(Table 4). There were few differences in illness perceptions between those in 
the two states. 
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Discussion 
Consultation costs were identified as the major driver of total healthcare 
utilisation costs in POFP and therefore also represent the main use of health 
services. The dichotomised GCPS state was identified as a good predictor of 
the total cost of healthcare utilisation and the high GCPS state was 
associated with significantly more biopsychosocial impact than the low GCPS 
state. Taking these two facts into consideration the dichotomised GCPS 
status may be used as a tool to better allocate resources.  As the GCPS is 
applicable and valid to all healthcare communities around the world this 
finding is applicable to any healthcare system, state-funded or private.  In all 
healthcare systems resources are finite and there is a desire to see resource 
used to the patient’s best advantage. The dichotomised GCPS may help 
determine stratified care pathways similar to those employed with great 
success in other persistent pain conditions (Hill et al. 2011), which would 
address the call for such a system recently issued by a qualitative 
examination of POFP care (Peters et al. 2015). 
 
There are several ways such a stratified model might work but one worth 
investigating might use a hub (specialist care centre) and spoke (community 
non-specialist screening and treatment centre) model and be initiated at the 
spoke by establishing dichotomised GCPS at first presentation. High GCPS 
status at first presentation would result in immediate expedited care from the 
hub as opposed to low GCPS, which would result in immediate care from the 
spoke. This putative system would offer the opportunity to rationalise 
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healthcare use, by focusing care on where it can be most useful. This may 
also help decrease the chances of further significant biopsychosocial impacts, 
and neuroplastic changes, especially in patients with higher-levels of pain 
related-disability, given that the optimisation of resources and the use of a full 
range of allied-health care professionals is likely to decrease waiting times. 
The use of this type of system might also help reduce the monetary and time 
costs in healthcare systems where large travelling distances exist between 
community and specialist settings. 
 
There are limitations to this study. Despite the wide sociodemographic range 
of the sample the cohort examined may not be representative of other 
populations. Dropout may have resulted in selection biases of differing types. 
Data may be subject to recall bias due to the time period of recall for 
individual’s use of healthcare. Recall bias and the differing modes of 
identifying healthcare use (interview versus questionnaire) may account for 
the higher healthcare costs over the last six months when compared to the 
per annum costs; for the former, some individuals were recalling utilisation 
over several years. Uncertainty around the ‘true’ unit costs of care also may 
mean that final total cost figures are subject to variation.  Nevertheless we 
explored this in extensive sensitivity analyses and the conclusions from these 
analyses remain the same as the main analysis.   
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This study provides quantitative corroboration of previous qualitative research 
data that suggest the healthcare pathway for POFP is complex and potentially 
‘consultation heavy’ (Durham et al. 2011; Durham and Nixdorf 2014; Peters et 
al. 2015). The data presented can be interpreted as either that people with 
POFP may have a protracted search themselves to find a cure, better pain 
management, or a diagnosis (Aggarwal et al. 2008; Durham et al. 2011; 
Peters et al. 2015). Or, that people with POFP have been given a diagnosis 
and management, but continue to exhibit further demand for treatment due to 
psychosocial co-morbidities and hence to continue to receive consultations 
(Barsky et al. 2001; Aggarwal et al. 2006). Whilst generic evidence exists that 
levels of somatization help predict healthcare use (Barsky et al. 2001) the 
evidence base for this in POFP is equivocal (Macfarlane et al. 1999). Given 
the qualitative data from published studies in the literature (Aggarwal et al. 
2008; Durham et al. 2011; Peters et al. 2015) and from the DEEP study itself 
(unpublished as yet) it is potentially more likely that some of the disparity 
between cost categories may be due to a lack of “ownership” of these 
patients; with patients falling between the two silos of dentistry and medicine. 
This leaves those affected without a defined care pathway and without a 
defined point of entry for more tailored and specific diagnosis and 
management. One way of preventing this would be to create a defined point 
of entry for anyone with orofacial pain persisting over three months at the 
spokes of the hub and spoke model. Using the dichotomised GCPS status to 
stratify care at first presentation to the spokes would help decrease the 
number of consultations which were the major driver of cost in this study, but 
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the question of whether allocation of more resource to one particular group of 
patients would be beneficial still remains to be answered. Answers to this 
question may be identified in the economic modelling of longitudinal data from 
the ongoing DEEP study. 
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Table 1 – Socioeconomic and demographic characteristics of sample 
 Characteristic 
  
 
 Screening result for origin 
of pain
1
   
MSK 
n=86 
NP/NV 
n=64 
COMB 
n=48 
Total 
n=198 
Age and gender           
n  (%) females !!
68 
(79.1) 
53 
 (82.8) 
39 
(81.2) 
160 
 (80.9) 
Age  (Mean[+/-SD])/yrs !!
52.9 
(±16.7) 
50.4    
(±15) 
51.9 
(±16.1) 
51.8 
(±16) 
n  (%) Ethnic origin           
 White British !!
77 
(89.5) 
38  
(59.4) 
43 
(89.6) 
158 
(79.8) 
White - any other white 
background !! 0(0) 0 (0) 1(2.1) 1 (0.5) 
Black or Black British - 
African !! 1(1.2) 0 (0) 0(0) 1 (0.5) 
Other - Chinese !! 0(0) 1 (1.6) 0(0) 1 (0.5) 
Other - Not known !! 0(0) 4 (6.2) 0(0) 4 (2) 
Undeclared !! 1(1.2) 5 (7.8) 1(2.1) 7 (3.5) 
Missing data !! 7(8.1) 16 (25) 3(6.2) 
26 
(13.1) 
Socioeconomic status           
n  (%) Highest 
educational level           
  
University - 
Postgraduate degree 
or diploma 
8 
(9.3) 
11 
(17.2) 
3 
(6.2) 
22 
(11.1) 
  
University - 
Undergraduate degree 
or diploma 
23 
(26.7) 
18 
(28.1) 
13 
(27.1) 
54 
(27.3) 
  
Vocational 
qualifications 
19 
(22.1) 
15 
(23.4) 
9 
(18.8) 
43 
(21.7) 
  
Secondary school 
public examinations -  
18 
(21.0) 
9 
(14.1) 
12 
(25.0) 
39 
(19.7) 
  
No public 
examinations  
13 
(15.1) 
4  
(6.2) 
6 
(12.5) 
23 
(11.6) 
  Missing data 
5 
(5.8) 
7  
(10.9) 
5 
(10.4) 
17  
(8.6) 
n  (%) Index of multiple 
deprivation decile 
ranking of home 
postcode
a 
          
  
10th & 9
th
  (Least 
deprived areas in UK) 
14 
(16.3) 
7 
(11.0) 
8  
(16.6) 
29 
(14.7) 
  8
th
 & 7th 
16 
(18.6) 
11 
(17.2) 
12 
(25.0) 
39 
(19.7) 
  6
th
 & 5th 
13 
(15.1) 
13 
(20.3) 
5 
(10.4) 
31 
(15.7) 
  4
th
 & 3rd 
20 
(23.2) 
8  
(12.5) 
16 
(33.3) 
44 
(22.3) 
  
2
nd
 & 1st  (Most 
deprived areas of UK) 22 25 
5  
(10.4) 52 
 Characteristic 
  
 
 Screening result for origin 
of pain
1
   
MSK 
n=86 
NP/NV 
n=64 
COMB 
n=48 
Total 
n=198 
(25.6) (39.1) (26.2) 
  Missing data 
1 
(1.2) 
0  
(0) 
2 
(4.2) 
3  
(1.5) 
n  (%) employed
b
   
53 
(61.6) 
42 
(65.6) 
21 
(43.8) 
116 
(58.6) 
 
Groups 1 - 3 
22 
(25.7) 
27 
(42.2) 
10 
(20.9) 
59 
(29.8) 
  Groups 4 - 6 
20 
(23.3) 
13 
(20.4) 6 (12.5) 
39 
(19.6) 
  Groups 7 - 9 
11 
(12.8) 2 (3.2) 5 (10.4) 18 (9.0) 
n  (%) unemployed   
7 
(8.1) 
9  
(14.1) 
11 
(22.9) 
27 
(13.6) 
n  (%) retired   
21 
(24.4) 
9  
(14.1) 
14 
(29.2) 
44 
(22.2) 
n  (%) sick leave 
because of POFP   0(0) 1 (1.6) 1(2.1) 2 (1) 
n  (%) student   3(3.5) 2 (3.1) 0(0) 5 (2.5) 
n  (%) missing data   2(1.2) 1 (1.6) 1(2.1) 4 (2.0) 
1
MSK - Musculoskeletal; NP/NV - Neuropathic/vascular; COMB - Combined origin derived 
from screening questionnaires used at entry to study (Hapak et al. 1994; Gonzalez et al. 
2011) 
a
Index of multiple deprivation (IMD) rank is calculated using the 2010 English census data 
which defined 32482 small geographic areas in England . Each of these areas was assessed 
on 38 domains and scored according to standardised criteria. Each area was then ranked 
from the best score (rank 1) to the worst (32482) according to IMD score. 
http://neighbourhood.statistics.gov.uk/dissemination/ 
b
Major group occupational categories from UK Office for National Statistics SOC 2010: Group 
1 - Managers, directors & senior officials; Group 2 - Professional occupations; Group 3 -
Associate professional & technical occupations; Group 4 - Administrative & secretarial 
occupations; Group 5 - Skilled trades occupations; Group 6 - Caring, leisure & other service 
occupations; Group 7 - Sales and customer service occupations; Group 8 - Process, plant & 
machine operatives; Group 9 - Elementary occupations 
POFP – Persistent Orofacial Pain 
 
Table 2 – Healthcare utilisation costs since complaint began 
Cost category 
  
Total cost 
since 
complaint 
began/£* 
Per annum 
cost over 
duration 
complaint/
£* 
Most 
recent 6 
months 
costs/£* 
Mean 
consultation 
costs         
  Primary medical care 444 106 194 
  Primary dental care 70 17 23 
  Physiotherapy 8 5 40 
  Secondary specialist care 732 147 321 
  
Total (Bootstrapped 
confidence interval
a
) 
1318 
(1034;1601) 
285 
(237;333) 
538 
(424;653) 
Mean 
medication 
costs by 
class of drug          
  
Simple analgesia 
(Paracetamol, NSAIDs) 2 1 2 
  Opioids 3 1 2 
  
Antidepressants (TCA, SSRI, 
SNRI) 5 1 9 
  Antiepileptics 22 7 21 
  
Migraine abortives and 
prophylactics (excluding 
antiepileptics) 9 1 3 
  Topical therapy 0 0 0 
  Anxiolytics 0 0 0 
  
Total (Bootstrapped 
confidence interval 
a
) 
41 
(31; 51) 
10 
(6;14) 
38 
(21;54) 
Mean 
appliance and 
intervention 
costs          
  Primary dental care 29 13 64 
  Secondary specialist care 321 54 2 
  
Total (Bootstrapped 
confidence interval 
a
) 
428 
(213;642) 
80 
(41;118) 
66 
(50;82) 
Overall total 
mean cost 
(Bootstrapped 
confidence 
interval 
a
)   
1751 
(1314;2189) 
362 
(291;433) 
642 
(525;758) 
a
Bootstrapped confidence intervals of the total cost using a bias corrected accelerated 
technique and 1000 repetitions 
*Currency is pounds sterling at 2012 prices, but can be converted to other national currencies 
using the validated Campbell and Cochrane Economics Methods Group (CCEMG) and 
Evidence for Policy and Practice Information and Coordinating Centre’s (EPPI-centre) Cost 
Converter (Shemilt et al. 2010) available at http://eppi.ioe.ac.uk/costconversion/ (last 
accessed 8
th
 March 2016) 
NSAIDS – Non Steroidal Anti-Inflammatory Drugs; TCA – Tricyclic antidepressants; SSRI – 
Selective Serotonin Reuptake Inhibitors; SNRI – Serotonin and Noradrenaline Reuptake 
Inhibitor 
 
Table 3 – Single predictor generalised gamma linear regression model 
(identity link function) adjusted for socioeconomic status and duration 
of pain 
Variable 
Coefficient
a
 95% 
Confidence 
Interval 
    
Dichotomised GCPS state (Low [0-IIa]; High [IIb-IV]) 366** 135 598 
    
Age group  
(Reference category: 20-29) 
   
30-39 125 -350 601 
40-49 102 -249 452 
50-59 -33 -412 347 
60-69 -173 -521 174 
70-79 -2 -543 539 
80-89 490 -171 1150 
  
 
 
Male (Reference category: female) 122 -118 361 
    
Duration of pain (Reference category: <1year) 
   
1-4 years 86 -85 257 
≥5years 129 -109 367 
 
 
  
Origin of pain  
(Reference category: musculoskeletal origin) 
   
Neuropathic/vascular -241** -413 -70 
Combined 67 -161 295 
    
Dichotomised IMD score  
(Reference category: bottom 50%) 
38 
 -125 200 
Education  
(Reference category: degree level education or higher) 
   
No public exams 227** 59 395 
Secondary exams 121 -24 265 
Economic activity  
(Reference category: "other" including unemployed, sick, 
and students) 
   
Employed -150 -466 167 
Retired -104 -480 273 
    
Constant 452* 95 809 
GCPS – graded chronic pain scale; IMD – Index of multiple deprivation  
**p<0.01; *p<0.05 
a
 – Coefficient is pounds sterling at 2012 prices. Interpretation example: those with no public 
exams compared to those with a degree level education cost, on average, £227 more for their 
health utilisation holding all other variables constant. Prices can be converted to other 
national currencies using the validated Campbell and Cochrane Economics Methods Group 
(CCEMG) and Evidence for Policy and Practice Information and Coordinating Centre’s (EPPI-
centre) Cost Converter (Shemilt et al. 2010) available at http://eppi.ioe.ac.uk/costconversion/ 
(last accessed 8
th
 March 2016) 
 
Table 4 - Psychosocial impact of pain by dichotomised GCPS state 
Instrument Domain 
Low GCPS (0-IIa) 
n=121 
High GCPS (IIb-IV) 
n=77 
  
Mean 
score 95% CI 
Mean 
score 95% CI 
MPI        
Pain impact subscales Pain severity 38.43 
35.54;  
41.32 54.17*** 
50.02;  
58.31 
  Interference 35.4 
32.75;    
38.04 52.29*** 
50.19;  
54.40 
  Life control 65.85 
62.26;  
69.44 52.83*** 
48.91;  
56.74 
  Affective distress 44.77 
42.01;  
47.53 54.95*** 
51.76;  
58.15 
  Support 48.9 
43.63;  
54.18 60.86* 
54.50;  
67.23 
Spousal interactions 
subscale 
Punishing 
responses 23.07 
18.34;  
27.81 30.59 
23.87;  
37.30 
  Soliciting responses 52 
48.26;  
55.75 57.57 
52.78;  
62.37 
  
Distracting 
responses 45.12 
40.36;  
49.89 51.7 
45.27;  
58.12 
          
PHQ-4 score  
   6.74 
6.16;  
7.32 8.63** 
7.77;  
9.49 
          
EQ-5D-5L utility value    0.75 
0.72;  
0.79 0.6*** 
0.54;  
0.65 
IPQ-R domains 
     
 
  
 
  Timeline 3.56 
3.42;  
3.70 3.77 
3.55;  
3.99 
  Consequences 2.55 
2.38;  
2.73 3.59*** 
3.37;  
3.81 
  Personal Control 2.96 
2.81;  
3.12 3.07 
2.90;  
3.25 
  Treatment control 3.15 
2.99;  
3.30 2.94 
2.75;  
3.12 
  Illness coherence 3.29 
3.08;  
3.49 3.18 
2.92;  
3.45 
  Timeline cyclical 3.52 
3.35;  
3.68 3.57 
3.35;  
3.79 
  
Emotional 
representations 2.95 
2.74;  
3.15 3.64*** 
3.42;  
3.86 
*  p<0.01 two tailed unpaired t-test between low and high GCPS status 
**p<0.001 two tailed unpaired t-test between low and high GCPS status 
***  p<0.0001 two tailed unpaired t-test between low and high GCPS status 
GCPS – Graded chronic pain scale;   MPI – West Haven Yale Multidimensional Pain 
Inventory;   IPQ-R – Illness Perceptions Questionnaire Revised form 
279 screened for eligibility 
239 recruited at baseline 
37 failed to respond to baseline data collection  
202 returned baseline data: 
199 complete datab 
3 partial datac 
40 excludeda: 
20 failed to return consent 
11 failed to meet inclusion criteria  
9 declined to participate after screening positive 
a"No"signiﬁcant"diﬀerence"in"age,"gender,"or"origin"of"pain"between"those"screening"posi6ve"who"agreed"to"par6cipate"and"
those"who"declined"involvement,""(p>0.05)."!
b!One"individual"withdrew"their"data"from"the"study"at"eighteen"month"data"collec6on"because"of"disagreement"with"the"
ques6onnaires."This"leE"198"complete"datasets"for"analysis!
cThree"individuals"stated"that"they"had"returned"baseline"but"no"data"was"received"and"they"were"unwilling"to"reIcomplete"
baseline"data"collec6on"and"although"they"con6nue"on"with"the"study"longitudinally"their"baseline"data"is"unavailable"for"
this"paper.!
!
Figure'1'–'Study'ﬂow'diagram'!
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Supplemental information on instruments employed 
EQ-5D-5L 
EQ-5D-5L is a generic health-related preference-based instrument, which 
examines problems in five domains: mobility, self-care, usual activities, 
pain/discomfort, anxiety/depression. In EQ-5D-5L participants are asked to 
score the problems experienced in each domain on a five point scale from 1 
(no interference or limitation) to 5 (maximum interference or limitation). The 
five responses are used to create an index ranging from 11111 (best possible 
health state) to 55555 (worst possible health state). The index is converted 
into a score using a scoring algorithm based on responses for the UK 
population.  This score ranges from -0.59 (55555, which is judged to be worse 
than death by the general population), through 0 (death), up to a maximum of 
1 (perfect health). At the time of writing normative data are only available for 
EQ-5D-3L, another version of the EQ-5D instrument but these data can be 
crosswalked to the EQ-5D 5L (van Hout et al. 2012).  It is anticipated that UK 
population data will be available by the end of the project for the EQ-5D 5L.  
Recommendations for imputation of missing EQ-5D data are given by Simons 
et al using multiple imputation (Simons et al. 2014) at the domain level and 
then calculating the utility score.  
Graded Chronic Pain Scale (GCPS) 
The GCPS is a measure of pain-related disability and intensity with normative 
data for population samples available (Elliott et al. 1999). It has seven items, 
six of which use numerical rating scales (0-10). Three of these six items 
examine average, worst, and current, pain intensity. The other three items 
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examine the individual’s level of disability in usual, daily, and 
recreational/social activities. These two groups of three items are both 
summed in their groups, then a mean taken of the individual’s scores and this 
mean multiplied by ten to generate a characteristic pain intensity (CPI) and a 
disability score respectively with higher scores indicating more pain or 
disability.  
The seventh item in the GCPS examines the number of days individuals have 
been prevented from their work, school or household activities in the last six 
months offering four predefined ranges for the respondent to chose from 
(“disability days”). An algorithm is provided to convert disability days, disability 
score, into disability points and then combine this with CPI to give a five point 
GCPS rating ranging from 0 to IV in order of ascending disability: 0 – no pain 
in past six months, to IV – High disability severely limiting. It is not possible to 
impute missing data on the GCPS individuals with missing data were 
therefore excluded from any analysis involving GCPS. 
Multidimensional Pain Inventory (MPI) 
The MPI is a multidimensional pain measure. Version 3 of the MPI was used 
as it generates scores using a Rasch modelling approach which is arguably 
the most robust of the three versions.  Only two of the three subscales of MPI 
are employed in this study, the pain impact and spousal interaction subscales. 
The third subscale examining interference in daily activity was omitted to 
decrease respondent burden in line with IMMPACT recommendations 
(Dworkin et al. 2005) as it covered similar constructs to those provided by 
GCPS and the EQ-5D-5L. The internal consistency (Cronbach alpha) of the 
subscales in this study were comparable to, or better than, those in previous 
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research using this instrument in toto (Kerns et al. 1985; Bergström et al. 
1999; Andreu et al. 2006): 
Table – Internal consistency (Cronbach’s alpha) of MPI subscales used in this study 
and those from: Kerns et al. 1985; Bergström et al. 1999; Andreu et al. 2006 
 Internal consistency (Cronbach’s alpha of subscale) 
MPI Sub-scale Current study Kerns et al '85
1
 Bergstrom et al 99
2
 Andreu et al 06
3
 
Pain severity 0.79 0.72 0.80 0.75 
Interference 0.93 0.90 0.86 0.85 
Life control 0.83 0.79 0.66 - 
Affective distress 0.72 0.73 0.80 0.75 
Support 0.90 0.83 0.81 0.82 
Punishing responses 0.91 0.84 0.86 0.78 
Soliciting responses 0.83 0.78 0.77 0.85 
Distracting responses 0.76 0.74 0.76 - 
1 Population sample of all types of chronic pain from hospital pain clinic n=120  
2 Population sample of chronic musculoskeletal pain (non-specific back or neck) from hospital rehabilitation 
clinics n=682 
3 Population sample Research Diagnostic Criteria (RDC/TMD) diagnosed TMD patients from specialist 
hospital clinic n=114. Life control and Distracting responses subscales data not given in paper 
 
All items in the MPI are rated either zero to six, or zero to four. Using MPI 
software (www.pain.pitt.edu/mpi) domain scores ranging from 0 to 100 were 
calculated for: pain severity, interference, life control, affective distress, 
support, punishing responses, soliciting responses, distracting responses. 
Higher scores in pain severity, interference, affective distress indicate a 
greater impact on the individual. Higher scores in life control and support 
indicate greater life control or greater amounts of support. Higher scores in 
the three “repsonses” domains indicate greater amounts of that type of 
response. Rasch modelling accounts for missing data and therefore no 
imputation is required. 
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Use of services and productivity questionnaire 
The use of services and productivity questionnaire (USPQ) used in this study 
was adapted from that proposed by Wordsworth and Thompson as a generic 
template for use of services and productivity questionnaires ((Wordsworth and 
Thompson 2001) available at http://www.dirum.org/instruments/details/28).  
The self-complete USPQ used in this study contained three sections that 
specifically examined costs encountered in the preceding six month period in 
relation to: consultations, medication and treatment, and productivity losses. 
Although indirect costs incurred by the patient were examined in the 
questionnaire the focus for this study is on the health care provider 
perspective and examples of the types of questions identifying healthcare 
utilisation from the perspective of the healthcare provider in the two sections 
relevant to this study (consultations, medication and treatment) are provided 
in brief below so that readers can comprehend how data were obtained on 
healthcare utilisation. The full version of the original USPQ is freely available 
at the website above. 
Consultations’ section 
The consultations’ section contained several questions in the form as below 
with X substituted for a range of healthcare providers (general medical 
practitioner, general dental practitioner, dental hospital specialist or consultant, 
medical hospital specialist or consultant, physiotherapist, psychologist, and 
other healthcare professional) to identify whether participants had seen 
particular healthcare professionals in the last six months in relation to their 
POFP and if so how many times they had seen them: 
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Have you seen X?   
Yes     No (move to question Y.Y)  
If yes, did you see them as an NHS patient? Yes     No  
How many times did you see the X?   
If you had to pay anything for your appointments, how much have you paid in total over the 
last six months?  £ - p 
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Medications and treatment section 
This section contained several questions related to whether participants had 
used specific groups of medications for their POFP including NSAIDs, opiates, 
Tricyclic Antidepressants, Antiepileptics, and “Other” medications, in the last 
six months. Drug classes were given in lay terminology along with specific 
examples of the types of drug that these classes would include in order to 
help remind people of the type of drugs in this group. The standard advice for 
the entire study was that if participants were in doubt when completing a 
question they could contact the research team or place a comment by the 
question and the research team would follow-up with them. An example of 
one of the medication questions is below: 
In the last six months, which of the following medications have been prescribed by 
your doctor/dentist (including tablets, capsules, inhalers, injections, creams, lotions 
and mixtures) to be used to manage your pain in your mouth and or face? You 
may chose more than one medication and for each medication chosen please give 
details of the medication’s total daily dose (the total amount in milligrams of the 
tablets you take per day) and whether you have used this medication regularly 
through each day or only when needed. 
You may find it helpful to look on the packaging of your medication to check its 
details. Please check the box ( ) against the groups you are using and give further 
details on those groups as indicated. If you are using none of the prescribed 
medications listed below in a-f please check this box  and go to question 2.4. 
a) Anti-inflammatory painkillers  
For example: Naproxen, Diclofenac (also known as Voltarol), Ibuprofen   
!
Please give name(s) of drug(s):       
Please indicate total daily dose  milligrams (mg) 
Used regularly  or as needed  
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Following the questions on medications participants were asked about any 
dental, medical, or surgical interventions they had experienced in the last six 
months in an attempt to address their POFP. Again a number of common 
interventions were specified along with an “other” category. Patients were 
asked to indicate if they had undergone the specified intervention and if it was 
provided by the NHS or by a private healthcare provider and if the latter how 
much they paid for it.  
There was also a final section in the questionnaire where participants could 
add in free-text any additional items they felt hadn’t been covered by the 
structured questions previously. The research team followed up any 
comments placed in this section that suggested costs that hadn’t been 
accounted for in the earlier sections of the questionnaire with the participant 
by telephone. 
 
Illness perceptions questionnaire (IPQ-R) 
The shortened version of the IPQ-R (http://www.uib.no/ipq/index.html) (Moss-
Morris et al. 2002), validated by Sniehotta et al (Sniehotta et al. 2010) , was 
used. This version consists of twenty-one items, which employ a five-point 
response scale: strongly disagree (1) to strongly agree (5). Appropriate items 
are summed in order to calculate seven domain scores: timeline; 
consequences; personal control; treatment control; illness coherence; timeline 
cyclical; emotional representations. With the exception of the personal and 
treatment control domains, higher domain scores represent less adaptive 
illness perceptions. Higher scores in the personal and treatment control 
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domains represent more adaptive illness perceptions.  Imputation guidelines 
(http://www.uib.no/ipq/index.html) state that up to one item missing per 
domain can be imputed using mean imputation based on responses for the 
other items in that domain. More than one item with missing data in each 
domain renders that domain’s score incalculable. There is no cumulative 
score for the questionnaire. 
Patient Health Questionnaire 4 (PHQ-4) 
The PHQ-4 is an ultra-brief screening instrument for anxiety and depression 
(Kroenke et al. 2009). It consists of two items from GAD-7 instrument (Spitzer 
et al. 2006) that screen for anxiety and two items from PHQ-9 instrument 
(Kroenke and Spitzer 2002) that screen for depression. All four items in PHQ-
4 are problem-based and use a four-point response scale ranging from: not all 
(0) to nearly every day (3).  
The item response codes are summed in their pairs in order to examine 
anxiety and depression: ≥3 is a “yellow flag” and ≥5 is a “red flag” for the 
relevant construct being examined (Kroenke et al. 2003; Lowe et al. 2005; 
Kroenke et al. 2007; Lowe et al. 2010). A cumulative score is then generated 
by summing all items’ response codes. Guidance for the thresholds of the 
cumulative score are that ≥6 is a ”yellow flag” and ≥9 is a “red flag” for anxiety 
or depression (Lowe et al. 2010). Given the small number of items in the 
instrument imputation is not possible and therefore if missing data were 
present in one domain both that domain and the cumulative score were 
incalculable. 
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Supplemental tables 
Table S1 – Unit costs and sources 
Cost category Unit cost* Source and calculation 
NHS Consultation costs     
Primary care     
General medical practitioner £62.90 Personal Social Services Research Unit’s 
(PSSRU) unit costs for healthcare (2012) 
General dental practitioner £17.50 Combination of data on the average consultation 
time in primary care (10.8minutes[±4.1] 
(Brocklehurst and Tickle 2011)), the British 
Dental Association’s standard contract for 
primary care (46 weeks per annum, working a 
35 hour week) and the 2012/13 dental earnings 
and expenses report from the Health and Social 
Care Information Centre [HSCIC] ((HSCIC 
2014); Average gross income £156,100) 
[((156200/46)/35)/60 = £1.62/minute of 
consultation]. Sensitivity analysis involved using 
the standard deviation of time per consultation to 
create upper and lower bounds 
Secondary care     
Oral Surgery new patient £123.00 Appropriate NHS mean reference cost for the 
financial year 2011-2012 (DoH 2012). Sensitivity 
analysis involved using the upper and lower 
bounds of the interquartile ranges 
Oral Surgery review patient £92.00   
Restorative dentistry new patient £108.00   
Restorative dentistry review patient £108.00   
Oral and Maxillofacial surgery new patient £110.00   
Oral and Maxillofacial surgery review patient £91.00   
Neurology new  patient £205.00   
Neurology review  patient £148.00   
Pain management new  patient £164.00   
Pain management review  patient £115.00   
Physiotherapy new  patient £49.00   
Physiotherapy review patient £43.00   
Rheumatology new £199.00   
Rheumatololgy review £128.00   
Opthalmology new £106.00   
Opthalmology review £80.00   
ENT new £109.00   
ENT review £83.00   
Clinical psychology new £89.00   
Clinical Psyhcology review £313.00   
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Liaison psychiatry new £178.00   
Liaison psychiatry review £208.00   
Emergency department new £122.00   
Emergency department review £121.00   
      
Medication costs     
Medication dosing regimens were combined 
with British National Formulary (Joint 
Formulary Committee 2012) price data to 
calculate the cost of pharmacological 
management. All medication costs were 
calculated using the non-proprietary version of 
the medication whenever possible. When 
patients could not recall, or obtain, their dosing 
regimen mean imputation from other users of 
that drug was used to impute the cost of that 
particular drug. 
    
      
NHS Procedure and appliance costs      
Primary dental care. 
Primary dental treatment costs are 
incorporated into the UDA value 
  Calculated using the number of units of dental 
activity (UDA) specified in the dental contract 
(NHS 2005) for the item of treatment reported 
multiplied by the average UDA cost (£25.61) for 
England and Wales in 2012 (BDA 2012) minus 
the patient contribution (NHS 2005) 
Cost to NHS for band 1 dental treatment non-
exempt. 1 UDA value 
Broad description of band:  
Examination, diagnosis, preventative care, x- 
rays, scale and polish 
 
£8.11 
Patient contribution £17.50 
Cost to NHS for band 2 dental treatment non-
exempt. 3 UDA value 
Broad description of band:  
Any of band 1 plus fillings, root canals, and 
extractions 
£28.83 
Patient contribution £48.00 
Cost to NHS for band 3 dental treatment non-
exempt. 12 UDA value 
Broad description of band:  
Any of band 1 or 2 plus crowns, bridges or 
dentures, or splints 
£98.32 
Patient contribution £209.00 
Cost to NHS for Urgent dental treatment non-
exempt. 1.2 UDA value.  
Broad description of band:  
Any emergency or out-of hour care. 
£13.23 
Patient contribution £17.50 
Secondary care     
Soft splint £57.00 Secondary care dental costs for hard 
stabilisation and soft splints were not available in 
the reference costs and were obtained from a 
local hospital 
Stabilisation splint £349.65   
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*Prices in pounds sterling at 2012 prices 
  
Out-patient tooth extraction £134.00 Taken as the mean national unit value from the 
appropriate NHS reference cost for the financial 
year 2011-2012 (DoH 2012). Sensitivity analysis 
involved using the upper and lower bounds of 
the interquartile ranges 
Sinus washout £1,082.00   
Salivary gland surgery £3,623.00   
Temporomandibular joint surgery £3,623.00   
Lumbar puncture £682.00   
Microvascular decompression Trigeminal 
nerve 
£10,084.00   
Ballon compression Trigeminal nerve £1,396.00   
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Table S2 – Pain history and impact 
 Pain characteristic or impact 
  
  
 Screening result for origin of pain
1
 
  
MSK 
n=86 
NP/NV 
n=64 
COMB 
n=48 
Total 
n=198 
Pain history. (Mean [+/-
SD]) 
Duration of 
pain/months 
88.5 
(±102.8) 
160.9 
(±173.2) 
74.2 
(±78.2) 
108.4 
(±130.3) 
  
Total number of visits 
primary care
a
 
11 
(±16.9) 
14 
(±15.4) 
14.3 
(±20.2) 
12.7 
(±17.3) 
  
Total number visits 
secondary specialist 
care
b
 
7.6 
(±13.8) 
6.7 
(±18.8) 
10 
(±30.8) 
7.9 
(±20.6) 
  
Total number of 
healthcare providers 
seen 
4.2 
(±2.4) 
2.8 
(±2.2) 
4 
(±2.2) 
3.7 
(±2.3) 
  
Total number of 
treatments attempted 
4.3 
(±4.1) 
3.7 
(±2.5) 
4.8 
(±4.7) 
4.2 
(±3.8) 
  
Most effective 
treatment score  (0 no 
effect - 10 resolved 
pain) 
5.9 
(±3.4) 
7.2 
(±3.2) 
6.3 
(±3.6) 
6.3 
(±3.4) 
GCPS            
 
Characteristic pain 
intensity (Mean [+/-
SD]) 
53.3  
(±20.9) 
48.5 
(±23.2) 
67.5 
(±17.5) 
55.3 
(±22.0) 
n (%) GCPS grade 0 
0 
(0) 
3  
(4.7) 
0 
(0) 
3  
(1.5) 
  1 
35 
(40.7) 
21 
(32.8) 
5 
(10.4) 
61 
(30.8) 
  2a 
26 
(30.2) 
13 
(20.3) 
18 
(37.5) 
57 
(28.8) 
  2b 
12 
(14) 
12 
(18.8) 
11 
(22.9) 
35 
(17.7) 
  3 
10 
(11.6) 
11 
(17.2) 
10 
(20.8) 
31 
(15.7) 
  4 
3 
(3.5) 
4  
(6.2) 
4 
(8.3) 
11 
(5.6) 
MPI  (Mean [+/-SD])           
  Pain severity 
42.4 
(±18.7) 
42.1 
(±15.4) 
51.6 
(±20.9) 
44.6 
(±18.6) 
  Interference 
38.9 
(±16.3) 
43.6 
(±13.9) 
45.3 
(±14.4) 
42 
(±15.3) 
  Life control 
63.5 
(±19.9) 
60.7 
(±19.3) 
56 
(±20.4) 
60.7 
(±19.9) 
  Affective distress 
47 
(±16.1) 
48.0 
(±12.2) 
52.9 
(±18.4) 
48.7 
(±15.6) 
  Support 
53.2 
(±26.7) 
58.7 
(±27.5) 
47.5 
(±35.2) 
53.6 
(±29.3) 
  Punishing responses 
23.6 
(±26.9) 
24.3 
(±27.2) 
32.6 
(±29.8) 
26.0 
(±27.8) 
  Soliciting responses 
53.5 
(±20.4) 
57.0 
(±20.8) 
51.7 
(±22.6) 
54.1 
(±21.1) 
  Distracting responses 
52.5 
(±26.3) 
40.6 
(±29.7) 
48.5 
(±24.4) 
47.7 
(±27.3) 
            
PHQ-4 score  (Mean 
[+/-SD])   
7.7 
(±3.5) 
6.6  
(±2.9) 
8.4 
(±4) 
7.5 
(±3.5) 
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 Pain characteristic or impact 
  
  
 Screening result for origin of pain
1
 
  
MSK 
n=86 
NP/NV 
n=64 
COMB 
n=48 
Total 
n=198 
EQ-5D-5L utility value  
(Mean[+/-SD])   
0.68 
(±0.229) 
0.760 
(±0.188) 
0.631 
(±0.222) 
0.694 
(±0.219) 
IPQ-R domain scores  
(Mean [+/-SD])           
  Timeline 4(±2.7) 
3.7 
(±0.7) 
5.5 
(±3.5) 
3.6 
(±0.9) 
  Consequences 
2.7 
(±1.1) 
3.3 
(±1.0) 
3.1 
(±1.1) 
3  
(±1.1) 
  Personal Control 
3.1 
(±0.9) 
2.9 
(±0.9) 
3.1 
(±0.8) 
3.0 
(±0.8) 
  Treatment control 
3.1 
(±0.9) 
3.1 
(±0.8) 
3.2 
(±1) 
3.1 
(±0.8) 
  Illness coherence 
3.5 
(±1.1) 
3  
(±1.2) 
3.2 
(±1.2) 
3.3 
(±1.1) 
  Timeline cyclical 
3.3 
(±1.1) 
3.8 
(±0.7) 
3.6 
(±1) 
3.5 
(±0.9) 
  
Emotional 
representations 
3.1 
(±1.2) 
3.3 
(±1.1) 
3.4 
(±1.1) 
3.2 
(±1.1) 
1
MSK - Musculoskeletal; NP/NV - Neuropathic/vascular; COMB - Combined origin derived 
from screening questionnaires used at entry to study (Hapak et al. 1994; Gonzalez et al. 
2011) 
a
Primary care defined as any (general) medical or dental practitioner or any other allied health 
professional seen in the community (including physiotherapy) 
b
Secondary care defined as any specialist health professional seen within a hospital setting 
GCPS – Graded chronic pain scale; MPI – West Haven Yale Multidimensional Pain Inventory; 
IPQ-R – Illness Perceptions Questionnaire Revised form 
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Table S3 – Mean costs by cost category and graded chronic pain status per annum and over the last six months 
 Cost category   Per annum 
costs* 
  Last six 
months 
costs* 
  
    GCPS Low GCPS High GCPS Low GCPS High 
Mean consultation costs            
  Primary medical care 79 145 152 259 
  Primary dental care 16 18 16 34 
  Physiotherapy 5 4 40 39 
  Secondary specialist care 134 163 260 412 
  Total 251 334 428 704 
  Bootstrapped confidence intervals for total 
cost
a
 
200;303 246;423 311;545 496;913 
Mean medication costs by 
class of drug  
          
  Simple analgesia (Paracetamol, NSAIDs) 1 1 1 2 
  Opioids 0 1 1 5 
  Antidepressants (TCA, SSRI, SNRI) 1 1 4 17 
  Antiepileptics 3 12 20 23 
  Migraine abortives and prophylactics 
(excluding antiepileptics) 
1 2 1 5 
  Topical therapy 0 0 0 1 
  Anxiolytics 0 0 0 0 
  Total 6 16 27 54 
  Bootstrapped confidence intervals for total 
cost
a
 
3;9 8;25 10;44 24;84 
Mean appliance and 
intervention costs  
          
  Primary dental care 12 15 66 61 
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 Cost category   Per annum 
costs* 
  Last six 
months 
costs* 
  
    GCPS Low GCPS High GCPS Low GCPS High 
  Secondary specialist care 50 59 3 0 
  Total 76 84 69 61 
  Bootstrapped confidence intervals for total 
cost
a
 
21;131 33;136 50;88 39;84 
Overall total mean cost   316 427 524 819 
Bootstrapped confidence 
intervals for total mean 
cost
a
 
  227;406 305;549 401;647 603;1036 
a
Bootstrapped using a bias corrected accelerated technique and 1000 repetitions 
*Prices in pounds sterling at 2012 prices 
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Table S4 – Sociodemographic and socioeconomic status by dichotomised 
GCPS group 
 Characteristic   
 Graded chronic 
pain scale (GCPS) 
dichotomised 
group   
    
GCPS Low (0-IIa)  
n=121 
GCPS High (IIb-IV) 
n=77 
Age and gender     
n  (%) females !! 97(80.2) 63(81.8) 
Age  (Mean[+/-SD])/yrs !! 53.9(±15.6) 48.7(±16.2) 
n  (%) Ethnic origin       
 White British !! 98(81) 60(77.9) 
White - any other white 
background !! 1(0.8) 0(0) 
Black or Black British - 
African !! 1(0.8) 0(0) 
Other - Chinese !! 0(0) 1(1.3) 
Other - Not known !! 3(2.5) 1(1.3) 
Undeclared !! 4(3.3) 3(3.9) 
Missing data !! 14(11.6) 12(15.6) 
Socioeconomic status       
n  (%) Highest 
educational level       
  
University - 
Postgraduate degree 
or diploma 13(10.7) 9(11.7) 
  
University - 
Undergraduate degree 
or diploma 33(27.3) 21(27.3) 
  
Vocational 
qualifications 30(24.8) 13(16.9) 
  
Secondary school 
public examinations - 
Age 18 5(4.1) 5(6.5) 
  
Secondary school 
public examinations - 
Age 16 14(11.6) 15(19.5) 
  
No public 
examinations  14(11.6) 9(11.7) 
  Missing data 12(9.9) 5(6.5) 
n  (%) Index of multiple 
deprivation decile 
ranking of home 
postcode
a 
      
  
10th  (Least deprived 
areas in UK) 5(4.1) 5(6.5) 
  9th 8(6.6) 11(14.3) 
  8th 13(10.7) 8(10.4) 
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 Characteristic   
 Graded chronic 
pain scale (GCPS) 
dichotomised 
group   
    
GCPS Low (0-IIa)  
n=121 
GCPS High (IIb-IV) 
n=77 
  7th 12(9.9) 6(7.8) 
  6th 7(5.8) 6(7.8) 
  5th 8(6.6) 10(13) 
  4th 23(19) 8(10.4) 
  3rd 4(3.3) 9(11.7) 
  2nd 19(15.7) 9(11.7) 
  
1st  (Most deprived 
areas of UK) 19(15.7) 5(6.5) 
  Missing data 3(2.5) 0(0) 
        
n  (%) employed
b
   75(62) 41(53.3) 
  
Managers, directors & 
senior officials 4(3.3) 1(1.3) 
  
Professional 
occupations 27(22.3) 12(15.6) 
  
Associate professional 
& technical 
occupations 8(6.6) 7(9.1) 
  
Administrative & 
secretarial 
occupations 18(14.9) 8(10.4) 
  
Skilled trades 
occupations 3(2.5) 1(1.3) 
  
Caring, leisure & other 
service occupations 5(4.1) 4(5.2) 
  
Sales and customer 
service occupations 5(4.1) 3(3.9) 
  
Process, plant & 
machine operatives 3(2.5) 1(1.3) 
  
Elementary 
occupations 2(1.7) 4(5.2) 
n  (%) unemployed   11(9.1) 16(20.8) 
n  (%) retired   29(24) 15(19.5) 
n  (%) sick leave 
because of COFP   1(0.8) 1(1.3) 
n  (%) student   4(3.3) 1(1.3) 
n  (%) missing data   1(0.8) 3(3.9) 
    
Pain history. (Mean [+/-
SD]) 
Duration of 
pain/months 110.1(±139.6) 105.9(±115.1) 
  
Total number of visits 
primary care
c
 11(±17) 15.6(±17.5) 
  
Total number visits 
secondary specialist 
care
d
 6.3(±12.4) 10.4(±29.1) 
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 Characteristic   
 Graded chronic 
pain scale (GCPS) 
dichotomised 
group   
    
GCPS Low (0-IIa)  
n=121 
GCPS High (IIb-IV) 
n=77 
  
Total number of 
healthcare providers 
seen 3.7(±2.5) 3.8(±2.2) 
  
Total number of 
treatments attempted 3.5(±2.7) 5.5(±5) 
  
Most effective 
treatment score  (0 no 
effect - 10 resolved 
pain) 6(±3.7) 7.1(±2.7) 
a
IMD rank is calculated using the 2010 English census data which defined 32482 small geographic 
areas in England . Each of these areas was assessed on 38 domains and scored according to 
standardised criteria. Each area was then ranked from the best score (rank 1) to the worst (32482) 
according to IMD score. http://neighbourhood.statistics.gov.uk/dissemination/ 
b
Major group occupational categories from UK Office for National Statistics SOC 2010 
c
Primary care defined as any (general) medical or dental practitioner or any other allied health 
professional seen in the community (including physiotherapy) 
d
Secondary care defined as any specialist health professional seen within a hospital setting 
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